In three cases, resolutions were supported relating to consumer protection: one called for reporting on pharmaceutical product availability in Canada (Wyeth); one related to prescription drug price controls (Pfizer Inc); and one supported product re-formatting and the removal of chemicals banned by the EU (CVS Corporation).